Anlotinib trials for Breast cancer

All Anlotinib trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Anlotinib for Breast cancer

• A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
  NCT07330544 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
  NCT06331169 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
  NCT06992336 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location

Common questions

How many trials study Anlotinib for Breast cancer?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.